Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05

FDA recall notice · announced February 2, 2022 · Aurobindo Pharma

Class II FDA/FSIS Class II: use may cause temporary or medically reversible adverse health consequences.

The product

Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05

Reason for recall

Superpotent and Failed Tablet/Capsule Specifications

Notes

Distribution: Nationwide in the US
Lot/code information: Batch # PF4520028B & PF4520028A, Exp. Date 11/2022
Quantity: 792 bottles
Status: Terminated
Products in this recall event:
- Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05 (D-0450-2022)

Source: U.S. Food and Drug Administration public recall data. This page reports official records and is not legal, medical, or repair advice.